Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261087 | 0.86 | MAPKAPK2 (0.47) | ATRMAPKAPK2CYP17A1 | |
| SCHEMBL17617988 | 0.84 | TYK2 (0.48) | ATRAAK1GRM5 | |
| SCHEMBL5838255 | 0.83 | ATR (0.47) | ATRAAK1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL18989831 | 0.82 | ATR (0.44) | ATRAAK1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL28850302 | 0.82 | SYK (0.50) | ATRLCKCYP17A1 | |
| SCHEMBL3909008 | 0.82 | STK17B (0.55) | ATRAAK1STK17BSTK17A | |
| SCHEMBL14883470 | 0.81 | AAK1 (0.39) | ATRAAK1STK17BSTK17AGRM5 | |
| SCHEMBL27267125 | 0.81 | ATR (0.45) | ATRMAPKAPK2GSK3BDYRK1AMETAP1 | |
| SCHEMBL17518970 | 0.80 | ATR (0.53) | ATRAAK1MAPKAPK2METAP1LCK | |
| SCHEMBL14907973 | 0.80 | STK17B (0.65) | AAK1STK17BSTK17ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-114846013-B | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-20 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240300946-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | disclosed |
| CN-117940424-A | EGFR inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117580841-A | Macrocyclic compounds and uses thereof | 特修斯制药公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-1675830-A4 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | SCIOS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1675830-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033072-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885AAK1 1731/4885STK17B 2337/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885AAK1 1731/4885STK17B 2337/4885 |
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | MAP4K2, MAP3K8, MAP3K2 | ATR 550/4885AAK1 477/4885STK17B 217/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885AAK1 1731/4885STK17B 2337/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | ATR 2715/4885AAK1 2474/4885STK17B 1869/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | ATR 4585/4885AAK1 1225/4885STK17B 2970/4885 |
| US-20240300946-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ATR 2692/4885AAK1 1074/4885STK17B 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.